Cargando…

Recent Advances in Assessing Immunogenicity of Therapeutic Proteins: Impact on Biotherapeutic Development

Detalles Bibliográficos
Autores principales:	Lu, Yanmei, Khawli, Leslie A., Purushothama, Shobha, Theil, Frank-Peter, Partridge, Michael A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2016
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5011518/ https://www.ncbi.nlm.nih.gov/pubmed/27642612 http://dx.doi.org/10.1155/2016/8141269

Ejemplares similares

Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins
por: Smith, Alison, et al.
Publicado: (2016)

Advances in the Development of Biotherapeutics
por: Oliveira, Pedro H., et al.
Publicado: (2015)

Posttranslational Modifications and the Immunogenicity of Biotherapeutics
por: Jefferis, Roy
Publicado: (2016)

Emerging Technologies and Generic Assays for the Detection of Anti-Drug Antibodies
por: Partridge, Michael A., et al.
Publicado: (2016)

Recent Advances in the Molecular Design and Applications of Multispecific Biotherapeutics
por: Zhong, Xiaotian, et al.
Publicado: (2021)

Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications
por: Kuriakose, Anshu, et al.
Publicado: (2016)

Recent advances in the treatment of C. difficile using biotherapeutic agents
por: Giau, Vo Van, et al.
Publicado: (2019)

Use of In Vitro Assays to Assess Immunogenicity Risk of Antibody-Based Biotherapeutics
por: Joubert, Marisa K., et al.
Publicado: (2016)

Integrated BioTherapeutics
por: Aman, M. Javad
Publicado: (2018)

The Development Pathway for Biosimilar Biotherapeutics
por: Zarbin, Marco
Publicado: (2020)

Immunogenicity to Biotherapeutics – The Role of Anti-drug Immune Complexes
por: Krishna, Murli, et al.
Publicado: (2016)

Impact of a Heat Shock Protein Impurity on the Immunogenicity of Biotherapeutic Monoclonal Antibodies
por: Rane, Shraddha S., et al.
Publicado: (2019)

Recent Advances in the Treatment of C. difficile Using Biotherapeutic Agents [Corrigendum]
Publicado: (2021)

In vivo selection of novel biotherapeutics
por: Ruozi, Giulia, et al.
Publicado: (2015)

Understanding preclinical and clinical immunogenicity risks in novel biotherapeutics development
por: Sauna, Zuben E., et al.
Publicado: (2023)

Investigation of pre-existing reactivity to biotherapeutics can uncover potential immunogenic epitopes and predict immunogenicity risk
por: Bivi, Nicoletta, et al.
Publicado: (2019)

Immunogenicity risk assessment for biotherapeutics through in vitro detection of CD134 and CD137 on T helper cells
por: Cohen, Sivan, et al.
Publicado: (2021)

Anti-Drug Antibodies: Emerging Approaches to Predict, Reduce or Reverse Biotherapeutic Immunogenicity
por: Pratt, Kathleen P.
Publicado: (2018)

Recent Advances in Antibody Therapeutics
por: Heo, Yong-Seok
Publicado: (2022)

Immunogenicity of glycans on biotherapeutic drugs produced in plant expression systems—The taliglucerase alfa story
por: Rup, Bonita, et al.
Publicado: (2017)

BioTherapeutics, Education and Research Foundation position paper: Assessing the competency of clinicians performing maggot therapy
por: Sherman, Ronald A., et al.
Publicado: (2021)

Advancements in Particle Engineering for Inhalation Delivery of Small Molecules and Biotherapeutics
por: Chang, Rachel Yoon Kyung, et al.
Publicado: (2022)

Microbiota-directed biotherapeutics: considerations for quality and functional assessment
por: Fekete, Emily Ef, et al.
Publicado: (2023)

Secukinumab, a novel anti–IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity
por: Karle, Anette, et al.
Publicado: (2016)

Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics
por: Martin, Kyle P., et al.
Publicado: (2023)

The Emerging Biotherapeutic Agent: Akkermansia
por: Kalia, Vipin Chandra, et al.
Publicado: (2021)

Editorial: Characterization of biotherapeutic products
por: Rathore, Anurag S., et al.
Publicado: (2022)

Validation of a Dendritic Cell and CD4+ T Cell Restimulation Assay Contributing to the Immunogenicity Risk Evaluation of Biotherapeutics
por: Siegel, Michel, et al.
Publicado: (2022)

Live Biotherapeutic Products, A Road Map for Safety Assessment
por: Rouanet, Alice, et al.
Publicado: (2020)

Regulatory Pathway for Licensing Biotherapeutics in Mexico
por: López-Morales, Carlos A., et al.
Publicado: (2018)

The impact of the human microbiome in tumorigenesis, cancer progression, and biotherapeutic development
por: Doocey, Claire M., et al.
Publicado: (2022)

Recent advances in lung organoid development and applications in disease modeling
por: Vazquez-Armendariz, Ana I., et al.
Publicado: (2023)

Recent Advances and Future Perspectives in the Development of Therapeutic Approaches for Neurodegenerative Diseases
por: Bowerman, Melissa
Publicado: (2020)

Pediatric Dosing and Body Size in Biotherapeutics
por: Shi, Rong, et al.
Publicado: (2010)

Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies
por: Husain, Bushra, et al.
Publicado: (2018)

Cyanobacterial Production of Biopharmaceutical and Biotherapeutic Proteins
por: Betterle, Nico, et al.
Publicado: (2020)

IgY Antibodies as Biotherapeutics in Biomedicine
por: León-Núñez, Diana, et al.
Publicado: (2022)

Principles of N-Linked Glycosylation Variations of IgG-Based Therapeutics: Pharmacokinetic and Functional Considerations
por: Boune, Souad, et al.
Publicado: (2020)

Recent Advances in Information Technology
por: Yu, Fei, et al.
Publicado: (2014)

Recent Advances in Plant Phenolics
por: Jacobo-Velázquez, Daniel A., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ie6dnurbke4g80kkif9p6hedgf